887565-40-4

Upstream product

• 211796-64-4 4-formyl-3-(trifluoromethyl)benzonitrile 
• 211796-64-4 4-dibromo-2-(trifluoromethyl)benzaldehyde 
• 261952-01-6 4-methyl-3-(trifluoromethyl)benzoic acid 
• 863248-28-6 4-(bromomethyl)-3-(trifluoromethyl)benzoic acid methyl ester 
• 116419-94-4 4-methyl-3-(trifluoromethyl)benzoic acid methyl ester 

Relevant academic research and scientific papers

Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties

Tumor-associated macrophages (TAMs) are predominantly associated with tumor growth. Colony-stimulating factor 1 receptor (CSF1R) acts as a key regulator of TAM survival and differentiation and is a molecular target for cancer therapies. Herein, novel CSF1

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed herewith) (I) which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.